In case you missed it, Jason Altmire, former Democratic three-term U.S. Representative from Pennsylvania and current adjunct professor at Texas Tech University, explains why so-called “delinking” proposals would be catastrophic for patients and families’ pocketbooks in a new op-ed in
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association (PCMA), highlights the opportunity Congress now has to get it right on drug pricing reforms in a new op-edpublished in RealClearHealth. He writes: “With
While Big Pharma pushes misguided policies targeting pharmacy benefits as part of a blame game designed to keep prescription drug prices high, former Members of Congress are reminding current lawmakers that they’ve seen this movie before. Congress has considered similar
Economic Analyses Shows “Delinking” Policy Hands Big Pharma a Financial Windfall totaling $32 Billion Annually (Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) issued the following statement on the introduction of H.R. 6283, “Delinking Revenue from Unfair Gouging Act” or
In case you missed it, Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former domestic policy adviser under the previous administration, asked Members of Congress a critical question in a new op-ed published in Townhall: Congress wants
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed are generics or biosimilars. During last week’s hearing in the House Oversight Committee, Dr. Rena
In case you missed it, Katie Payne, senior vice president for strategic communications for the Pharmaceutical Care Management Association (PCMA), discusses how the BIO International Convention happening this week in Boston, MA misses the critical opportunity to address the root
In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy benefit companies underscored that misguided policies targeting pharmacy benefits will lead to higher prescription drug
Ike Brannon, former senior economist for the United States Treasury and U.S. Congress, and Anthony Lo Sasso, professor of economics at DePaul University, explain the role of pharmacy benefit companies in the prescription drug supply chain in a new Forbes
©2024 PCMA. All Rights Reserved.
